Analysts Set Avantor, Inc. (NYSE:AVTR) Price Target at $12.00

Shares of Avantor, Inc. (NYSE:AVTR) have received a consensus rating of “Hold” from the eighteen analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and two have assigned a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $12.00.

AVTR has been the subject of several analyst reports. Royal Bank Of Canada increased their price objective on Avantor from $9.00 to $14.00 and gave the company a “sector perform” rating in a report on Thursday, July 30th. TD Cowen restated a “hold” rating on shares of Avantor in a research note on Wednesday, July 15th. Wells Fargo & Company boosted their price target on Avantor from $14.00 to $16.00 and gave the stock an “overweight” rating in a research note on Thursday, July 30th. Jefferies Financial Group raised shares of Avantor from an “underperform” rating to a “hold” rating and set a $13.00 price target for the company in a report on Wednesday, July 29th. Finally, Morgan Stanley lifted their price objective on shares of Avantor from $10.00 to $14.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th.

Institutional Investors Weigh In On Avantor

A number of institutional investors and hedge funds have recently modified their holdings of AVTR. EverSource Wealth Advisors LLC increased its holdings in Avantor by 119.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,187 shares of the company’s stock worth $29,000 after buying an additional 1,189 shares during the period. Private Trust Co. NA increased its stake in shares of Avantor by 46.2% in the fourth quarter. Private Trust Co. NA now owns 2,769 shares of the company’s stock worth $32,000 after acquiring an additional 875 shares during the period. Strategic Wealth Investment Group LLC purchased a new position in shares of Avantor during the second quarter worth $32,000. Los Angeles Capital Management LLC purchased a new position in shares of Avantor during the fourth quarter worth $32,000. Finally, Osaic Holdings Inc. lifted its position in Avantor by 60.9% during the second quarter. Osaic Holdings Inc. now owns 2,810 shares of the company’s stock valued at $38,000 after purchasing an additional 1,064 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Stock Up 1.4%

Shares of Avantor stock opened at $14.45 on Tuesday. The company has a quick ratio of 1.18, a current ratio of 1.78 and a debt-to-equity ratio of 0.65. The company has a market cap of $9.77 billion, a P/E ratio of -17.20, a PEG ratio of 10.91 and a beta of 0.89. The firm’s 50 day moving average price is $11.63 and its 200-day moving average price is $9.65. Avantor has a 52-week low of $7.26 and a 52-week high of $15.93.

Avantor (NYSE:AVTR) last posted its earnings results on Wednesday, July 29th. The company reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.02. The company had revenue of $1.69 billion during the quarter, compared to analysts’ expectations of $1.61 billion. Avantor had a negative net margin of 8.81% and a positive return on equity of 9.92%. Avantor’s revenue for the quarter was up .5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.24 earnings per share. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. On average, sell-side analysts predict that Avantor will post 0.81 EPS for the current fiscal year.

About Avantor

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.